European regulators Struggle with Globalisation of Clinical Trials - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

European regulators Struggle with Globalisation of Clinical Trials
The globalisation of clinical trials is putting pressure on the European Medicines Agency.

Pharmaceutical Technology Europe
Volume 24, Issue 6


The globalisation of clinical trials is now an accepted trend, although not all observers are content about the way it has developed and continues to progress. Documented cases of unethical conduct during clinical trials have led to both public and media outcry, and have prompted calls in the European Parliament for the stronger enforcement of international standards. The EMA has comeunder heavy criticism over its role in overseeing trials conducted on foreign territories, although it argues that it is responding to the need for better regulation and intends to become transparent regarding its future activities in this field.


1. F. Thiers et al, Nature Reviews Drug Discovery, 7, 13–14 (2008).

2. S. Glickman et al. N. Engl. J. Med., 360, 816–823 (2009).

3. China Clinical Trials Outsourcing Congress, "Welcome to the 4th Annual China Clinical Trials Outsourcing Congress" (Event website, 2012)., accessed 30 April 2012.

4. J. Aronson, British Medical Journal, 326(7396), 990 (2003).

5. BBC News Anger at deadly Nigerian drug trials. <, accessed 8th May 2012

6. BBC News. Pfizer denies dirty tricks claims in Nigeria. < accessed 8th May 2012.

7. The Guardian, 2012. Pfizer pays out to Nigerian families of meningitis drug trial victims. <, accessed 8th May 2012.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here